WE CLAIM:

5 1. A compound represented by formula I or a pharmaceutically acceptable salt or a prodrug derivative thereof:

wherein;

R and R' are independently C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> fluoroalkyl, or together R and R' form a substituted or unsubstituted, saturated or unsaturated carbocyclic ring having from 3 to 8 carbon atoms;


R<sub>PH</sub> is hydrogen or methyl;


R1 and R2 are independently selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> fluoroalkyl, -O-C<sub>1</sub>-C<sub>5</sub> alkyl, -S-C<sub>1</sub>-C<sub>5</sub> alkyl, -O-C<sub>1</sub>-C<sub>5</sub> fluoroalkyl, -CN, -NO<sub>2</sub>, acetyl, -S-C<sub>1</sub>-C<sub>5</sub> fluoroalkyl, C<sub>2</sub>-C<sub>5</sub> alkenyl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl, and C<sub>3</sub>-C<sub>5</sub> cycloalkenyl;

 $L_1$  and  $L_2$  and  $L_3$  are divalent linking groups independently selected from the group consisting of

a bond , 
$$X_1$$
 ...  $(CH_2)_m$  ...  $C$  ...  $OH$  ...  $(CH_2)_m$  ...  $CH$  ...  $(CH_2)_m$  ...  $(CH_$ 

-111-





where m is 0, 1 or 2, X<sub>1</sub> is oxygen or sulfur, and each R40 is independently hydrogen,

C<sub>1</sub>-C<sub>5</sub> alkyl, or C<sub>1</sub>-C<sub>5</sub> fluoroalkyl; 5

RBOH is 3-methyl-3-hydroxypentyl, 3-methyl-3-hydroxypentenyl, 3-methyl-3-hydroxypentynyl, 3-ethyl-3-hydroxypentyl, 10 3-ethyl-3-hydroxypentenyl, 3-ethyl-3-hydroxypentynyl, 3-ethyl-3-hydroxy-4-methylpentyl, 3-ethyl-3-hydroxy-4-methylpentenyl, 3-ethyl-3-hydroxy-4-methylpentynyl, 15 3-propyl-3-hydroxypentyl, 3-propyl-3-hydroxypentenyl, 3-propyl-3-hydroxypentynyl, 1-hydroxy-2-methyl-1-(methylethyl)propyl, 1-hydroxycycyclopentenyl, 20 1-hydroxycyclohexenyl, 1-hydroxycycloheptenyl, 1-hydroxycyclooctenyl, 1-hydroxycyclopropyl, 1-hydroxycyclobutyl, 1-hydroxycyclopentyl,

30

-113-

1-hydroxycyclohexyl,

1-hydroxycycloheptyl, or

1-hydroxycyclooctyl; provided, however, that when 5 R<sub>BOH</sub> is 3-methyl-3-hydroxypentyl, 3-methyl-3-hydroxypentenyl, 3-methyl-3-hydroxypentynyl, 3-ethyl-3-hydroxypentyl, 3-ethyl-3-hydroxypentenyl, · 10 3-ethyl-3-hydroxypentynyl, 3-ethyl-3-hydroxy-4-methylpentyl, 3-ethyl-3-hydroxy-4-methylpentenyl, 3-ethyl-3-hydroxy-4-methylpentynyl, 3-propyl-3-hydroxypentyl, 15 3-propyl-3-hydroxypentenyl, 3-propyl-3-hydroxypentynyl, or 1-hydroxy-2-methyl-1-(methylethyl)propyl; then L<sub>1</sub> and L<sub>2</sub> combine as a bond; and R<sub>C</sub> is 20 -CO<sub>2</sub>H, -CO<sub>2</sub>Me, -CO<sub>2</sub>Et, -C(O)CH<sub>2</sub>S(O)Me,  $-C(O)CH_2S(O)Et$ , 25  $-C(O)CH_2S(O)_2Me$ ,  $-C(O)CH_2S(O)_2Et$ ,

-C(O)CH<sub>2</sub>CH<sub>2</sub>S(O)Me,

-C(O)CH<sub>2</sub>CH<sub>2</sub>S(O)Et,

-C(O)CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>Me,

-C(O)CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>Et,

-C(O)CHMeCH<sub>2</sub>CO<sub>2</sub>H

-114-

	-C(O)C(O)OH,
	$-C(O)C(O)NH_2,$
	-C(O)C(O)NHMe,
	-C(O)C(O)NMe2,
5	-C(O)NH <sub>2</sub> , C(O)NMe <sub>2</sub> ,
	-C(O)NHS(O)Me,
	-C(O)NHSO <sub>2</sub> Me,
	-C(O)-NH-5-tetrazolyl,
	-C(O)NMe-5-tetrazolyl,
10	-C(O)NHS(O)Me,
	-C(O)NHS(O)Et,
	-C(O)NHSO <sub>2</sub> Me,
	-C(O)NHSO <sub>2</sub> Et,
	-C(O)NHS(O)iPr,
15	-C(O)NHSO2iPr,
	-C(O)NHS(O)nPr,
	-C(O)NHSO <sub>2</sub> nPr,
	-C(O)NHCH <sub>2</sub> S(O)Me,
	-C(O)NHCH <sub>2</sub> S(O)Et,
20	-C(O)NHCH <sub>2</sub> SO <sub>2</sub> Me,
	-C(O)NHCH2SO2Et,
•	-C(O)NHCH2CH2S(O)Me,
	-C(O)NHCH2CH2S(O)Et,
	-C(O)NHCH2CH2SO2Me,
25	-C(O)NHCH2CH2SO2Et,
	$-C(O)NH_2,$
	-C(O)NMe <sub>2</sub> ,
	-C(O)NH-CH <sub>2</sub> -C(O)OH,
	-C(O)NH-CH(Me)-C(O)OH,
30	-C(O)NH-CH(F)-C(O)OH,
	-C(O)NH-CH(CF <sub>3</sub> )-C(O)OH,
	-C(O)NH-CH(OH)-C(O)OH,

## -115-

	-C(O)NH-CH(cyclopropyl)-C(O)OH,
	$-C(O)NH-C(Me)_2-C(O)OH$ ,
	-C(O)NH-C(Me) <sub>2</sub> -C(O)OH,
	-C(O)NH-CF(Me)-C(O)OH,
· 5	-C(O)NH-C(Me)(CF <sub>3</sub> )-C(O)OH,
-	-C(O)NH-C(Me)(OH)-C(O)OH,
· -	-C(O)NH-C(Me)(cyclopropyl-C(O)OH,
•	-C(O)NMe-CH <sub>2</sub> -C(O)OH,
	-C(O)NMe-CH(Me)-C(O)OH,
10	-C(O)NMe-CH(F)-C(O)OH,
	-C(O)NMe-CH(CF <sub>3</sub> )-C(O)OH,
	-C(O)NMe-CH(OH)-C(O)OH,
:	-C(O)NMe-CH(cyclopropyl)-C(O)OH,
	-C(O)NMe-C(Me) <sub>2</sub> -C(O)OH,
15 <sup>-</sup>	-C(O)NMe-CF(Me)-C(O)OH,
	-C(O)NMe-C(Me)(CF <sub>3</sub> )-C(O)OH,
	-C(O)NMe-C(Me)(OH)-C(O)OH,
	-C(O)NMe-C(Me)(cyclopropyl)-C(O)OH,
•	-CH <sub>2</sub> -CO <sub>2</sub> H,
20	-CH <sub>2</sub> -5-tetrazolyl,
	-CH <sub>2</sub> CO <sub>2</sub> Me,
	-CH <sub>2</sub> CO <sub>2</sub> Et,
	-CH <sub>2</sub> NHS(O)Me,
:	-CH <sub>2</sub> NHS(O)Et,
25	-CH <sub>2</sub> NHSO <sub>2</sub> Me,
	-CH <sub>2</sub> NHSO <sub>2</sub> Et,
	-CH2NHS(O)iPr,
•	-CH <sub>2</sub> NHSO <sub>2</sub> iPr,
	-CH <sub>2</sub> NHS(O)nPr,
30	-CH <sub>2</sub> NHSO <sub>2</sub> nPr,
	-CH <sub>2</sub> NHCH <sub>2</sub> CH <sub>2</sub> SO <sub>2</sub> CH <sub>3</sub> ,
	-CH <sub>2</sub> NH(CH <sub>2</sub> CO <sub>2</sub> H),

## -116-

	•	
•	-CH <sub>2</sub> N(C(O)Me)(CH <sub>2</sub> CO <sub>2</sub> H),	:
	-CH <sub>2</sub> -N-pyrrolidin-2-one,	,·
•	-CH <sub>2</sub> -(1-methylpyrrolidin-2-one-3-yl),	
	-CH <sub>2</sub> S(O)Me,	
5 .	-CH <sub>2</sub> S(O)Et,	•
•	-CH <sub>2</sub> S(O) <sub>2</sub> Me,	
· -	-CH <sub>2</sub> S(O) <sub>2</sub> Et,	•
	-CH <sub>2</sub> S(O)iPr,	-
	-CH <sub>2</sub> S(O) <sub>2</sub> iPr,	•
10	-CH <sub>2</sub> S(O)nPr,	•
•	-CH <sub>2</sub> S(O) <sub>2</sub> nPr,	
	-CH <sub>2</sub> CO <sub>2</sub> H, CH <sub>2</sub> C(O)NH <sub>2</sub> ,	· · ·
	-CH <sub>2</sub> C(O)NMe <sub>2</sub> ,	
	-CH <sub>2</sub> C(O)NHMe,	. •
15	-CH <sub>2</sub> C(O)-N-pyrrolidine,	•
	-CH <sub>2</sub> S(O) <sub>2</sub> Me,	
	-CH <sub>2</sub> S(O)Me,	
	-CH(OH) CO <sub>2</sub> H,	
·	$-CH(OH)C(O)NH_2,$	•
20	-CH(OH)C(O)NHMe,	
•	-CH(OH)C(O)NMe <sub>2</sub> ,	•
	-CH(OH)C(O)NEt <sub>2</sub> ,	
	-CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H,	
•	-CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> Me,	•
.25	-CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> Et,	•
	$-CH_2CH_2C(O)NH_2$ ,	•
	-CH <sub>2</sub> CH <sub>2</sub> C(O)NHMe,	
•	-CH <sub>2</sub> CH <sub>2</sub> C(O)NMe <sub>2</sub> ,	
	-CH <sub>2</sub> CH <sub>2</sub> -5-tetrazolyl,	• •
30	-CH <sub>2</sub> CH <sub>2</sub> S(O) <sub>2</sub> Me,	
	-CH <sub>2</sub> CH <sub>2</sub> S(O)Me,	
	-CH <sub>2</sub> CH <sub>2</sub> S(O) <sub>2</sub> Et,	

-117-

-CH<sub>2</sub>CH<sub>2</sub>S(O) Et,

-CH<sub>2</sub>CH<sub>2</sub>S(O)iPr,

-CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>iPr,

-CH<sub>2</sub>CH<sub>2</sub>S(O)nPr,

-CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>nPr,

 $-CH_2CH_2S(O)NH_2$ ,

-CH<sub>2</sub>CH<sub>2</sub>S(O)NHMe,

-CH<sub>2</sub>CH<sub>2</sub>S(O)NMe<sub>2</sub>,

 $-CH_2CH_2S(O)_2NH_2$ ,

-CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>NHMe,

-CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>NMe<sub>2</sub>,

-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S(O)Me,

-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S(O)Et,

-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>Me,

-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>Et,

-CH(Me)CH<sub>2</sub>C(O)OH,

-C(Me)<sub>2</sub>CH<sub>2</sub>C(O)OH,

-SO<sub>3</sub>H,

-5-tetrazolyl,

5

10

15

. 20

-118-


or

- -1,3,4-oxadiazolin-2-one-5-yl,
- -imidazolidine-2,4-dione-5-yl,
- -1,3-thiazolidine-2,4-dione-5-methylidene,
- -isoxazol-3-ol-yl, or
- -1,3,4-oxadiazolin-2-thione-5-yl.


2. A compound according to Claim 1 or a pharmaceutically acceptable salt or ester prodrug derivative thereof wherein

R<sub>PH</sub> is hydrogen;


L<sub>3</sub> are divalent linking groups independently selected from the group consisting of











---NH---S(O)---

-NH

---CH<sub>2</sub>---S(O)----, and

--o-s(o)--- ; and

R<sub>C</sub> is

-CO<sub>2</sub>H,

-CO<sub>2</sub>Me,

-CO<sub>2</sub>Et,

-C(O)CH<sub>2</sub>S(O)Me,

-C(O)CH<sub>2</sub>S(O)Et,

 $-C(O)CH_2S(O)_2Me$ ,

 $-C(O)CH_2S(O)_2Et$ ,

-C(O)CH<sub>2</sub>CH<sub>2</sub>S(O)Me,

-C(O)CH<sub>2</sub>CH<sub>2</sub>S(O)Et,

15

10

	ı	
	•	-C(O)CH2CH2S(O)2Me,
		-C(O)CH2CH2S(O)2Et,
•		-C(O)CHMeCH <sub>2</sub> CO <sub>2</sub> H
	·	-C(O)C(O)OH,
5	-	$-C(O)C(O)NH_2,$
		-C(O)C(O)NHMe,
		-C(O)C(O)NMe2,
		$-C(O)NH_2$ , $C(O)NMe_2$ ,
		-C(O)NHS(O)Me,
10		-C(O)NHSO <sub>2</sub> Me,
		-C(O)-NH-5-tetrazolyl,
		-C(O)NMe-5-tetrazolyl,
		-C(O)NHS(O)Me,
		-C(O)NHS(O)Et,
15		-C(O)NHSO <sub>2</sub> Me,
		-C(O)NHSO <sub>2</sub> Et,
		-C(O)NHS(O)iPr,
		-C(O)NHSO2iPr,
		-C(O)NHS(O)nPr,
20		-C(O)NHSO <sub>2</sub> nPr,
		-C(O)NHCH <sub>2</sub> S(O)Me,
		-C(O)NHCH <sub>2</sub> S(O)Et,
		-C(O)NHCH <sub>2</sub> SO <sub>2</sub> Me,
•		-C(O)NHCH <sub>2</sub> SO <sub>2</sub> Et,
25		-C(O)NHCH2CH2S(O)Me,
	•	-C(O)NHCH2CH2S(O)Et,
	•	-C(O)NHCH2CH2SO2Me,
	•	-C(O)NHCH2CH2SO2Et,
		$-C(O)NH_2$ ,
30		-C(O)NMe <sub>2</sub> ,
		-C(O)NH-CH <sub>2</sub> -C(O)OH,
		-C(O)NH-CH(Me)-C(O)OH,

## -123-

	-C(O)NH-CH(F)-C(O)OH,
	-C(O)NH-CH(CF <sub>3</sub> )-C(O)OH,
	-C(O)NH-CH(OH)-C(O)OH,
	-C(O)NH-CH(cyclopropyl)-C(O)OH,
5	-C(O)NH-C(Me) <sub>2</sub> -C(O)OH,
•	-C(O)NH-C(Me) <sub>2</sub> -C(O)OH,
	-C(O)NH-CF(Me)-C(O)OH,
	-C(O)NH-C(Me)(CF <sub>3</sub> )-C(O)OH,
	-C(O)NH-C(Me)(OH)-C(O)OH,
10	-C(O)NH-C(Me)(cyclopropyl-C(O)OH,
•	-C(O)NMe-CH <sub>2</sub> -C(O)OH,
	-C(O)NMe-CH(Me)-C(O)OH,
	-C(O)NMe-CH(F)-C(O)OH,
-	-C(O)NMe-CH(CF <sub>3</sub> )-C(O)OH,
15	-C(O)NMe-CH(OH)-C(O)OH,
	-C(O)NMe-CH(cyclopropyl)-C(O)OH,
	-C(O)NMe-C(Me) <sub>2</sub> -C(O)OH,
	-C(O)NMe-CF(Me)-C(O)OH,
	-C(O)NMe-C(Me)(CF <sub>3</sub> )-C(O)OH,
20	-C(O)NMe-C(Me)(OH)-C(O)OH,
•	-C(O)NMe-C(Me)(cyclopropyl)-C(O)OH,

-124-

 $-CH_2-CO_2H$ , -CH<sub>2</sub>-5-tetrazolyl, -CH<sub>2</sub> CO<sub>2</sub>Me, -CH<sub>2</sub>CO<sub>2</sub>Et, -CH<sub>2</sub>NHS(O)Me, 5 -CH<sub>2</sub>NHS(O)Et, -CH<sub>2</sub>NHSO<sub>2</sub>Me, -CH<sub>2</sub>NHSO<sub>2</sub>Et, -CH<sub>2</sub>NHS(O)iPr, -CH<sub>2</sub>NHSO<sub>2</sub>iPr, 10 -CH<sub>2</sub>NHS(O)nPr, -CH<sub>2</sub>NHSO<sub>2</sub>nPr,  $\hbox{-CH}_2\hbox{NHCH}_2\hbox{CH}_2\hbox{SO}_2\hbox{CH}_3,$  $-CH_2NH(CH_2CO_2H),$  $-CH_2N(C(O)Me)(CH_2CO_2H),$ 15 -CH<sub>2</sub>-N-pyrrolidin-2-one, -CH<sub>2</sub>-(1-methylpyrrolidin-2-one-3-yl), -CH<sub>2</sub>S(O)Me, -CH<sub>2</sub>S(O)Et, -CH<sub>2</sub>S(O)<sub>2</sub>Me,20 -CH<sub>2</sub>S(O)<sub>2</sub>Et, -CH<sub>2</sub>S(O)iPr, -CH<sub>2</sub>S(O)<sub>2</sub>iPr,-CH<sub>2</sub>S(O)nPr,  $-CH_2S(O)_2nPr$ , 25 - $CH_2CO_2H$ ,  $CH_2C(O)NH_2$ ,  $-CH_2C(O)NMe_2$ , -CH<sub>2</sub>C(O)NHMe, -CH<sub>2</sub>C(O)-N-pyrrolidine, -CH<sub>2</sub>S(O)<sub>2</sub>Me,30 -CH<sub>2</sub>S(O)Me, -CH(OH) CO<sub>2</sub>H,

-125-

	$-CH(OH)C(O)NH_2$
•	-CH(OH)C(O)NHMe,
	-CH(OH)C(O)NMe2,
	-CH(OH)C(O)NEt <sub>2</sub> ,
5	-CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H,
	-CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> Me,
•	-CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> Et,
·	-CH <sub>2</sub> CH <sub>2</sub> C(O)NH <sub>2</sub> ,
-	-CH <sub>2</sub> CH <sub>2</sub> C(O)NHMe,
10	-CH <sub>2</sub> CH <sub>2</sub> C(O)NMe <sub>2</sub> ,
	-CH <sub>2</sub> CH <sub>2</sub> -5-tetrazolyl,
•	-CH <sub>2</sub> CH <sub>2</sub> S(O) <sub>2</sub> Me,
	-CH <sub>2</sub> CH <sub>2</sub> S(O)Me,
	-CH <sub>2</sub> CH <sub>2</sub> S(O) <sub>2</sub> Et,
15	-CH <sub>2</sub> CH <sub>2</sub> S(O) Et,
,	-CH <sub>2</sub> CH <sub>2</sub> S(O)iPr,
	-CH <sub>2</sub> CH <sub>2</sub> S(O) <sub>2</sub> iPr,
•	-CH <sub>2</sub> CH <sub>2</sub> S(O)nPr,
	-CH <sub>2</sub> CH <sub>2</sub> S(O) <sub>2</sub> nPr,
20	-CH <sub>2</sub> CH <sub>2</sub> S(O)NH <sub>2</sub> ,
	-CH <sub>2</sub> CH <sub>2</sub> S(O)NHMe,
·	-CH <sub>2</sub> CH <sub>2</sub> S(O)NMe <sub>2</sub> ,
	- $CH_2CH_2S(O)_2NH_2$ ,
. :	-CH <sub>2</sub> CH <sub>2</sub> S(O) <sub>2</sub> NHMe,
25 .	-CH <sub>2</sub> CH <sub>2</sub> S(O) <sub>2</sub> NMe <sub>2</sub> ,
,	-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> S(O)Me,
<u>.</u>	-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> S(O)Et,
	-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> S(O) <sub>2</sub> Me,
	-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> S(O) <sub>2</sub> Et,
30	
	u

-SO<sub>3</sub>H,

-126-

-5-tetrazolyl,

or

- -1,3,4-oxadiazolin-2-one-5-yl,
- -imidazolidine-2,4-dione-5-yl,
- -1,3-thiazolidine-2,4-dione-5-methylidene,
- -isoxazol-3-ol-yl, or
- -1,3,4-oxadiazolin-2-thione-5-yl.


3. A compound represented by formula (II) or a pharmaceutically acceptable salt or an ester prodrug derivative thereof:

$$R_{ROH}$$
 $R_{ROH}$ 
 $R_{ROH}$ 

wherein;

R and R' are independently methyl or ethyl;

R1 and R2 are independently hydrogen, halo, -CF3, methyl, ethyl, or cyclopropyl;  $L_1$  and  $L_2$  are independently divalent linking groups independently selected from



where m is 0 or 1;

RBOH is selected from

15

1-hydroxycycyclopentenyl,

1-hydroxycyclohexenyl,

1-hydroxycyclopentyl, or

1-hydroxycyclohexyl, and

R<sub>C</sub> is a group selected from

	•	-CO <sub>2</sub> H,
		-CO <sub>2</sub> Me,
	•	-CO <sub>2</sub> Et,
	•	$-C(O)NH_2$ ,
5		-C(O)NMe <sub>2</sub> ,
		$-C(O)NH-CH_2-C(O)OH$ ,
-	-	-C(O)NH-CH(Me)-C(O)OH,
	-	-C(O)NH-CH(F)-C(O)OH,
		-C(O)NH-CH(CF <sub>3</sub> )-C(O)OH,
10		-C(O)NH-CH(OH)-C(O)OH,
		-C(O)NH-CH(cyclopropyl)-C(O)OH,
		$-C(O)NH-C(Me)_2-C(O)OH$ ,
	•	-C(O)NH-C(Me) <sub>2</sub> -C(O)OH,
		-C(O)NH-CF(Me)-C(O)OH,
15		-C(O)NH-C(Me)(CF <sub>3</sub> )-C(O)OH,
		-C(O)NH-C(Me)(OH)-C(O)OH,
		-C(O)NH-C(Me)(cyclopropyl-C(O)OH,
		-C(O)NMe-CH <sub>2</sub> -C(O)OH,
		-C(O)NMe-CH(Me)-C(O)OH,
20		-C(O)NMe-CH(F)-C(O)OH,
		-C(O)NMe-CH(CF <sub>3</sub> )-C(O)OH,
		-C(O)NMe-CH(OH)-C(O)OH,
	•	-C(O)NMe-CH(cyclopropyl)-C(O)OH,
•	•	-C(O)NMe-C(Me) <sub>2</sub> -C(O)OH,
25	•	-C(O)NMe-CF(Me)-C(O)OH,
		-C(O)NMe-C(Me)(CF <sub>3</sub> )-C(O)OH,
		-C(O)NMe-C(Me)(OH)-C(O)OH,
•	·	-C(O)NMe-5-tetrazolyl,
		-C(O)NMe-C(Me)(cyclopropyl)-C(O)OH, or
30		-C(O)-NH-5-tetrazolyl.

4. A compound represented by formula (III) or a pharmaceutically acceptable salt or an ester prodrug derivative thereof:

$$R_{BOH}$$
 $R_{1}$ 
 $R_{2}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{1}$ 
 $R_{2}$ 

wherein;

R and R' are independently methyl or ethyl;

R1 and R2 are independently hydrogen, halo, -CF3, methyl, ethyl, or cyclopropyl; RBOH is selected from

3-methyl-3-hydroxypentyl,

3-methyl-3-hydroxypentenyl,

3-methyl-3-hydroxypentynyl,

3-ethyl-3-hydroxypentyl,

3-ethyl-3-hydroxypentenyl,

3-ethyl-3-hydroxypentynyl,

3-propyl-3-hydroxypentyl,

3-propyl-3-hydroxypentenyl,

3-propyl-3-hydroxypentynyl,

3-ethyl-3-hydroxy-4-methylpentyl,

3-ethyl-3-hydroxy-4-methylpentenyl,

3-ethyl-3-hydroxy-4-methylpentynyl, or

1-hydroxy-2-methyl-1-(methylethyl)propyl;

and

R<sub>C</sub> is a group selected from

-CO<sub>2</sub>H,

-CO<sub>2</sub>Me,

-CO<sub>2</sub>Et,

-C(O)NH<sub>2</sub>,

 $-C(O)NMe_2$ ,

-C(O)NH-CH<sub>2</sub>-C(O)OH,

-C(O)NH-CH(Me)-C(O)OH,

10

15

20

-131-

-C(O)NH-CH(F)-C(O)OH, -C(O)NH-CH(CF<sub>3</sub>)-C(O)OH, -C(O)NH-CH(OH)-C(O)OH, -C(O)NH-CH(cyclopropyl)-C(O)OH,  $-C(O)NH-C(Me)_2-C(O)OH$ , 5  $-C(O)NH-C(Me)_2-C(O)OH$ , -C(O)NH-CF(Me)-C(O)OH, -C(O)NH-C(Me)(CF<sub>3</sub>)-C(O)OH, -C(O)NH-C(Me)(OH)-C(O)OH, -C(O)NH-C(Me)(cyclopropyl-C(O)OH, 10 -C(O)NMe-CH<sub>2</sub>-C(O)OH, -C(O)NMe-CH(Me)-C(O)OH, -C(O)NMe-CH(F)-C(O)OH, -C(O)NMe-CH(CF<sub>3</sub>)-C(O)OH, -C(O)NMe-CH(OH)-C(O)OH, 15 -C(O)NMe-CH(cyclopropyl)-C(O)OH, -C(O)NMe-C(Me)<sub>2</sub>-C(O)OH, -C(O)NMe-CF(Me)-C(O)OH,  $-C(O)NMe-C(Me)(CF_3)-C(O)OH$ , -C(O)NMe-C(Me)(OH)-C(O)OH, 20 -C(O)NMe-5-tetrazolyl, -C(O)NMe-C(Me)(cyclopropyl)-C(O)OH, or -C(O)-NH-5-tetrazolyl.

5. The compound represented by formula (AA-1) to (AA-33) or a pharmaceutically acceptable salt or prodrug derivative thereof:

AA-1)

AA-2)

AA-3)

AA-4)

5

AA-5)

AA-6)

AA-7)

AA-8)

5

AA-9)

-134-

AA-10)

AA-11)

AA-12)

5

AA-13)

AA-14)

AA-15)

AA-16)

5

AA-17)

-136-

AA-18)

AA-19)

AA-20)

5

AA-21)

AA-22)

AA-23)

AA-24)

5

AA-25)

AA-26)

AA-27)

AA-28)

5

AA-29).

AA-30) ·

AA-31)

AA-32)

5

AA-33)

6. The compound represented by formula (BB-1) to (BB-33)or a pharmaceutically acceptable salt or prodrug derivative thereof:

5 BB-1)

BB-2)

BB-3)

-141-

BB-4)

BB-5)

5 **BB-6**)

BB-7)

BB-8)

BB-9)

BB-10)

BB-11)

5

BB-12)

BB-13)

BB-14)

BB-15)

5

BB-16)

-144-

BB-17)

BB-18)

BB-19)

BB-20)

-145-

BB-21)

BB-22)

BB-23)

5

BB-24)

BB-25)

BB-26)

BB-27)

BB-28)

-147-

BB-29)

BB-30)

BB-31)

5

BB-32)

BB-33)

7. The compound represented by formula (CC-1) to (CC-44) or a pharmaceutically acceptable salt or prodrug derivative thereof:

CC-1)

CC-2)

-149-

CC-3)

CC-4)

5 CC-5)

CC-6)

CC-7)

-150-

CC-8)

CC-9)

CC-10)

5

CC-11)

CC-12)

CC-13)

CC-14)

5

CC-15)

-152-

CC-16)

5

CC-17)

CC-18)

CC-19)

CC-20)

5 CC-21)

CC-22)

CC-23)

-154-

CC-24)

CC-25)

CC-26)

5

CC-27)

-155-

CC-28)

CC-29)

CC-30)

5

CC-31)

CC-32)

CC-33)

CC-34)

5

CC-35)

-157-

CC-36)

CC-37)

5.

CC-38)

CC-39)

-158-

CC-40)

CC-41)

CC-42)

. 5

CC-43)

$$HO \longrightarrow O \longrightarrow O \longrightarrow O \longrightarrow O \longrightarrow O$$

5

8. The compound represented by the formula:

or a pharmaceutically acceptable salt or prodrug derivative thereof.

10

9. The compound represented by the formula:

or a pharmaceutically acceptable salt or prodrug derivative thereof.

-160-

- 10. The prodrug derivative of the compound of claim 1 to 9 wherein the prodrug is a methyl ester; ethyl ester; N,N-diethylglycolamido ester; or morpholinylethyl ester.
- 11. The salt derivative of the compound of claim 1 to 9 wherein the salt is sodium 5 or potassium.
  - 12. A pharmaceutical formulation comprising the compound of claim 1 to 9 together with a pharmaceutically acceptable carrier or diluent.
- 10 13. A formulation for treating osteoporosis comprising:

Ingredient (A1): the vitamin D receptor modulator of claim 1, represented by formula (I);

Ingredient (B1):

one or more co-agents selected from the group consisting of:

a. estrogens,

b. androgens,

c. calcium supplements,

d. vitamin D metabolites,

e. thiazide diuretics,

f. calcitonin,

g. bisphosphonates,

h. SERMS, and

i. fluorides; and

Ingredient (C1): optionally, a carrier or diluent.

25

20

- 14. The formulation of claim 13 wherein the weight ratio of (A1) to (B1) is from 10:1 to 1:1000.
  - 15. A formulation for treating osteoporosis comprising:

Ingredient (A2): the vitamin D receptor modulator of claim 1 represented by formula (I);

Ingredient (B2):

PCT/US2004/037182

5

10

15

20

25

one or more co-agents that are conventional for treatment osteoporosis selected from the group consisting of:

- a. topical glucocorticoids,
- b. salicylic acid,
- c. crude coal tar; and

Ingredient (C2): optionally, a carrier or diluent.

- 16. The formulation of claim 15 wherein the weight ratio of (A2) to (B2) is from 1:10 to 1:100000.
- 17. A method of treating a mammal to prevent or alleviate the pathological effects of Acne, Actinic keratosis, Alopecia, Alzheimer's disease, Bone maintenance in zero gravity, Bone fracture healing, Breast cancer, Chemoprovention of Cancer, Crohn's disease, Colon cancer, Type I diabetes, Host-graft rejection, Hypercalcemia, Type II diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum secretion, Osteomalacia, Osteoporosis, Insufficient dermal firmness, Insufficient dermal hydration, Psoriatic arthritis, Prostate cancer, Psoriasis, Renal osteodystrophy, Rheumatoid arthritis, Scleroderma, Skin cancer, Systemic lupus erythematosus, Skin cell protection from, Mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles; wherein the method comprises administering a pharmaceutically effective amount of at least one compound of claim 1 or 9.
  - 18. The method of claim 17 for the treatment of psoriasis.
  - 19. The method of claim 17 for the treatment of osteoporosis.
- 20. A method of claim 17 for treating a mammal to prevent or alleviate skin cell protection from Mustard vesicants.
- 21. A method of of treating a mammal to prevent or alleviate the pathological effects of Benign prostatic hyperplasia or bladder cancer wherein the method comprises administering a pharmaceutically effective amount of at least one compound of claim 1 or

9.

- 22. A method of treating or preventing disease states mediated by the Vitamin D receptor, wherein a mammal in need thereof is administered a pharmaceutically effective amount of the compound of Claim 1 to 9.
  - 23. A compound as claimed in any one of Claims 1 to 9 for use in treating a mammal to prevent or alleviate the pathological effects of Acne, Actinic keratosis, Alopecia, Alzheimer's disease, Bone maintenance in zero gravity,
- Bone fracture healing, Breast cancer, Chemoprovention of Cancer, Crohn's disease,
  Colon cancer, Type I diabetes, Host-graft rejection, Hypercalcemia, Type II diabetes,
  Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum secretion,
  Osteomalacia, Osteoporosis, Insufficient dermal firmness, Insufficient dermal hydration,
  Psoriatic arthritis, Prostate cancer, Psoriasis, Renal osteodystrophy, Rheumatoid arthritis,
  Scleroderma, Skin cancer, Systemic lupus erythematosus, Skin cell protection from,
  Mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles.
  - 24. A compound as claimed in any one of Claims 1 to 9 for use in treating or preventing disease states mediated by the Vitamin D receptor.

20

- 25. A compound as claimed in any one of Claims 1 to 9 for use in treating a mammal to prevent or alleviate the pathological effects of Benign prostatic hyperplasia or bladder cancer.
- 26. A compound as claimed in Claim 1 substantially as hereinbefore described with reference to any of the Examples.
  - 27. A process for preparing a compound as claimed in claim 1 substantially as hereinbefore described with reference to any of the Examples.

28. The use of a compound as claimed in claim 1 substantially as herein described with reference to any of the Assays and Tables for mediating the Vitamin D receptor.

## This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record.

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
DREFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.